Cold agglutinin disease
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
4 regimens on this page
4 variants on this page
|
All lines of treatment
BR
| back to top |
BR: Bendamustine, Rituximab
Regimen
| Study | Evidence |
| Berentsen et al. 2017 | Phase II |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
28-day cycle for 4 cycles
References
- Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017 Jul 27;130(4):537-541. Epub 2017 May 22. link to original article contains verified protocol PubMed
Eculizumab (Soliris)
| back to top |
Regimen
| Study | Evidence |
| Röth et al. 2015 (DECADE) | Phase II, <20 pts |
Eligible patients had symptomatic cold agglutinin-mediated hemolysis with a serum lactate dehydrogenase (LDH) level greater than or equal to 2 x upper limit of normal and a cold agglutinin titer greater than 1:64 at 4°C.
- Eculizumab (Soliris) 600 mg IV once per week for 4 weeks, then 900 mg IV once on week 5, then 900 mg IV every 2 weeks
Supportive medications:
- Patients were vaccinated against Neisseria meningitidis or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose
26-week course
References
- Abstract: Alexander Röth, MD, Martin Bommer, MD, Andreas Hüttmann, MD, Dörte Herich-Terhürne, Nils Kuklik, PhD, Lenz Veronika, Hubert Schrezenmeier, MD and Ulrich Dührsen, MD. Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial). ASH Annual Meeting 2015 Abstract 274 link to abstract
Fludarabine & Rituximab
| back to top |
Regimen
| Study | Evidence |
| Berentsen et al. 2010 | Phase II |
Eligible patients had to be diagnosed with cold agglutinin disease and require therapy because of anemia, substantial cold-induced circulatory symptoms, or both.
- Fludarabine (Fludara) 40 mg/m2 PO once per day on days 1 to 5, 29 to 34, 57 to 61, 85 to 89
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 29, 57, 85
One course
References
- Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, Jacobsen EM, Thoresen AS, Beiske K, Tjønnfjord GE. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010 Oct 28;116(17):3180-4. Epub 2010 Jul 15. link to original article contains verified protocol PubMed
Rituximab (Rituxan)
| back to top |
Regimen
| Study | Evidence |
| Berentsen et al. 2003 | Phase II |
| Schöllkopf et al. 2006 | Phase II |
Patients in Berentsen et al. 2003 were required to have cold agglutinin disease, as defined by the combination of chronic hemolysis and a cold agglutinin titer of 1:64 or higher, and a typical pattern for the direct antiglobulin test (DAT).
- Rituximab (Rituxan) 375 mg/m2 IV once per week
4-week course
References
- Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004 Apr 15;103(8):2925-8. Epub 2003 Dec 30. link to original article contains verified protocol PubMed
- Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, Jensen BA, Pedersen BB, Taaning EB, Klausen TW, Birgens H. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006 Feb;47(2):253-60. link to original article contains protocol PubMed